MedTrace Logo

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

NCT00384033 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 638

Last updated 2012-03-15

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

Desvenlafaxine Succinate Sustained-Release (DVS SR)

50 mg tablet, once daily dosing for 8 weeks

DRUG

Desvenlafaxine Succinate Sustained-Release (DVS SR)

100 mg tablet, once daily dosing for 8 weeks

DRUG

Placebo

Matching placebo tablets and capsules, once daily dosing for 8 weeks

DRUG

Duloxetine 60 mg/day

60 mg capsule, once daily dosing for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00384033 on ClinicalTrials.gov